|Day Low/High||117.39 / 118.62|
|52 Wk Low/High||91.76 / 126.07|
As consumer confidence and health care spending soar, Johnson & Johnson is becoming one of the best total return packages available.
Amgen's effort to improve disappointing sales of its multiple myeloma drug Kyprolis took a hit Tuesday with the failure of a phase III clinical trial involving newly diagnosed patients.
Stocks end Monday's session sharply lower as Wall Street grows restless ahead of the first presidential debate.
Stocks hold near session lows by mid-afternoon Monday as Wall Street grows restless ahead of the first presidential debate.
Stocks are lower Monday as Wall Street's attention shifts to the looming presidential debate from central bank policy.
Johnson & Johnson's pullback my have finally reached an end. Here's how to trade the stock now.
Focus on finding stocks of high-quality companies at good prices, Cramer advises.
Brace for extreme turbulence as Mylan's chief executive testifies before Congress and faces further public condemnation.
A New Commitment to 2030 Sustainable Development Goals and Ongoing Support for Refugees
The deal comes as Abbott works to complete two pending transactions worth nearly $40 billion combined and is the latest in the slew of ophthalmology deals.
Johnson & Johnson (JNJ) is buying Abbott Laboratories (ABT) medical optics division, which deals with vision care services such as laser vision correction, for $4.3 billion.
Acquisition to Strengthen Global Leadership in Eye Health Adding Cataract and Refractive Eye Surgery to Vision Care Portfolio
Johnson & Johnson (JNJ) agreed to buy 100 megawatts from a wind-power development in the Texas Panhandle, a move that furthers the company's existing $339 million invested in clean-energy projects.
Pay attention to what companies are doing to improve themselves, not the hand-wringing from fund managers about Fed intervention.
The medical device company taps Jason Hannon, an 11-year company veteran, as its new president and COO, succeeding Patrick Miles, who was appointed vice chairman.
Drug companies like Merck, Pfizer and Johnson & Johnson are spending big bucks on the opposition of Proposition 61.
Preparations also underway to initiate first-in-human study for multivalent vaccine regimen to combat Ebola, Sudan and Marburg viruses
When the market decides only one thing is working, that makes things treacherous for everyone else,
In the last year, shares of Boston Scientific are up almost 50%. Boston Scientific is putting the problems of the past behind it and has a bright future.
Karyopharm announced study results in which its experimental drug selinexor demonstrated a 20% tumor response rate in multiple myeloma patients no longer responsive to four or five currently approved therapies.
Each of these companies pays extremely safe dividends, yields over 2%, and doesn't appear to be extremely overvalued like many other dividend-paying stocks in the market today.
Johnson & Johnson, the most consistent dividend stock in the world with 54 consecutive increases, has also had 32 straight adjusted earnings-per-share increases.
Jim Cramer ponders the presidential campaign tradition of corporate bashing and how the stock market is more important than the Fed.